APR 23, 2026
Standing out in a competitive landscape: The power of structure-based biologics design
In a competitive landscape, the success of a biologics program depends on the ability to identify high-quality candidates early. Traditional experimental screening approaches are often limited in that they are directed to a singular function of the protein, carry liabilities, or have relatively low hit rates. Schrödinger’s protein design toolkit, powered by Protein FEP+, offers a way to rapidly ideate and assess multiple key features of best-in-class therapeutics. Through computational optimization with advanced, but easy to use, in silico methods, biologists can de-risk molecules and improve experimental hit rates. Affinity, pH dependent affinity, specificity, stability, developability, and more can be evaluated in silico, enabling more efficient prioritization of molecules and delivering superior biologics with a >4x speed-up in development cycles.
Join our upcoming webinar to learn how to leverage advanced in silico methods to de-risk your molecules and increase your experimental success rates.
Highlights:
- Intro to advanced in silico methods: An overview of high-fidelity structure-based modeling for modern biologics discovery
- How to de-risk and optimize hit rates: How high-accuracy computational prioritization ensures you spend lab time only on the most promising candidates
- FEP+ 101 for biologists: Understanding the physics-based workflow for high-accuracy affinity and stability predictions across diverse modalities
- See it in action: A walkthrough of in silico lead optimization and residue scanning workflows in a real-world design context
Who should attend:
- Bench Biologists and Protein Engineers looking for easy-to-use, comprehensive models to surpass the limitations of empirical screening
- Current MM-GBSA Users seeking higher-fidelity predictions to identify superior variants and gain a competitive advantage
- R&D Directors and VPs focused on engineering best-in-class biologics and accelerating their path to the clinic
- Principal Investigators interested in modernizing their research with high-precision, structure-based design workflows
Our Speaker
Dan Cannon
Director, Product Management, Applications Science, Schrödinger
Dan Cannon, Director, Head of Biologics Modelling is responsible for advancing Schrödinger’s biologics modelling platform capabilities. He is also the Product Manager for Schrödinger’s Protein Design Services. Dan received his Ph.D. from the University of Strathclyde in Glasgow, UK, under the supervision of Prof. Tell Tuttle. In 2016, he began working at MedImmune (now AstraZeneca) in Cambridge, UK, using computational approaches for therapeutic protein design before joining Schrödinger in August of 2018 as an Applications Scientist. Dan continues to publish novel approaches towards structure-based protein design and develop innovative computational solutions for the rational design of biologics.
8:30 AM – 9:00 AM 
